Purchase Order FA864925P0352
- Not listed
- The U.S. Air Force Research Laboratory (AFRL) has awarded a $1,797,867.00 Small Business Innovation Research (SBIR) Phase II contract to Matregenix Inc., a minority-owned and self-certified small disadvantaged business based in Irvine, California. The contract, titled "DERMASPIN: HANDHELD DEVICE FOR CONTACTLESS APPLICATION OF AN ANTIBACTERIAL NANOFIBER MATRIX FOR RAPID WOUND HEALING AT THE POINT-OF-CARE," is a firm fixed-price purchase order with a completion date of May 18, 2026....
- The Department of the Air Force Materiel Command Research Laboratory awarded a $109,921 firm fixed price Small Business Innovation Research Phase I contract to Matregenix Inc. to develop a handheld device for contactless application of an antibacterial nanofiber matrix to rapidly heal wounds at the point-of-care. The total small business set-aside contract has a period of performance through March 2024. Matregenix Inc. is a minority-owned, self-certified small disadvantaged manufacturer...
- This is a $74,472 firm fixed-price purchase order awarded by the Air Force Research Laboratory (AFRL) to Matregenix Inc., a minority-owned, self-certified small disadvantaged business manufacturer based in Mission Viejo, California. The contract is part of the Small Business Innovation Research (SBIR) program and is for the development of novel bi-layer biologically-free amino acid nanofiber membranes to enhance dental and craniomaxillofacial surgery outcomes through improved guided bone...
- This is a $74,628 firm-fixed-price SBIR Phase I contract awarded by the U.S. Air Force Research Laboratory (AFRL) to Matregenix Inc., a minority-owned small business. The contract supports Matregenix's proposal titled "MATRINOVA: A BIOLOGICALLY-FREE AMINO-ACID NANOFIBER REVOLUTIONIZING SOFT TISSUE RESTORATION WITH SIMPLIFIED LOGISTICS AND EXTENDED SHELF LIFE." This SBIR award aims to develop a biologically-free nanofiber material with simplified logistics and extended shelf life for...
- This is a firm fixed-price purchase order contract awarded by the Air Force Research Laboratory (AFRL) to Matregenix Inc., a minority-owned, self-certified small disadvantaged business located in Mission Viejo, California. The contract, valued at $1,248,992.00, is for the development of a biologically-free amino-acid nanofiber for rotator cuff repair with enhanced shelf life and simplified logistics, under the Small Business Innovation Research (SBIR) Program Phase II. The contract is set...
- <p>The U.S. Air Force Research Laboratory awarded a $49,935.00 Firm Fixed Price purchase order to Primelabs LLC, a Minority Owned, Self Certified Small Disadvantaged Business, for Trauma Care Management for Acute Compartment Syndrome under the Small Business Innovation Research (SBIR) Program Phase I Action. The contract, which has a completion date of May 3, 2021, is set aside for small businesses. Primelabs LLC, a limited liability company, is the prime contractor for this award.</p>
- This is a $1,700,000.00 Small Business Innovation Research (SBIR) Phase II contract awarded by the Air Force Research Laboratory (AFRL) to Critical Innovations LLC, a small business medical research and development company. The contract is for the development of a fully-qualified manufacturing system for the automated, on-demand, point-of-use production of qualified devices for use in space logistics support by Space Force end users. The contract is a firm-fixed-price purchase order with a...
- This is a $2,994,281.25 Firm Fixed Price contract awarded by the Defense Health Agency (DHA) to Paranano Wound Care LLC, a small business, under the SBIR (Small Business Innovation Research) program. The contract is for Phase II of a project titled "The BIOZ Smart Bandage Empowering Priority Response to Pathogen Invasion in Wounds" and has an ultimate completion date of July 11, 2027. The contract is focused on medical research and development related to wound care and pathogen...
- The U.S. Air Force Research Laboratory (AFRL) awarded a $1,249,991.91 Firm Fixed Price SBIR Phase II contract to Stone Solutions And Research Collective LLC, a minority-owned, service-disabled veteran-owned small business located in Phoenix, Arizona. The contract is for the "Multi-Capable Airman Training Research for Interface Experience (MATRIX)" project, which involves developing advanced software interfaces, training systems, and operational technologies to enhance military...
- This is a Phase I Small Business Innovation Research (SBIR) contract awarded by the Department of the Army Medical Command to CFD Research Corporation, a small business, on September 25, 2017 for $149,946.59. The contract is for the research and development of "VASCULARIZATION OF THICK TISSUE CONSTRUCTS FOR REGENERATIVE MEDICINE APPLICATIONS." CFD Research is a small business that provides engineering, modeling, and simulation services to federal agencies including the Department of...
The U.S. Air Force Research Laboratory (AFRL) awarded a $1.25 million Phase II Small Business Innovation Research (SBIR) contract to Matregenix Inc., a minority-owned small disadvantaged business based in Mission Viejo, California. This total small business set-aside contract, awarded on July 18, 2025, supports the development of a surge-capable, non-biologic amino acid-based wound-healing matrix designed specifically for rapid trauma care and streamlined military logistics. The contract is structured as a firm fixed price purchase order with a completion date of April 18, 2027, and represents a continuation of AFRL's investment in Matregenix's innovative medical technologies. Matregenix specializes in advanced nanofiber-based biomaterials and medical devices with particular expertise in developing synthetic, biologically-free solutions for wound healing and tissue restoration. The company's track record includes multiple SBIR and STTR awards focused on creating shelf-stable, logistically simplified medical technologies tailored to military healthcare requirements. This Phase II effort builds on the company's demonstrated capabilities in synthetic membrane technology and is expected to advance the delivery of deployable wound-care solutions that eliminate reliance on animal-derived or biologic materials, thereby reducing complexity in field medical applications.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2m | 7/23/25 |